FOR IMMEDIATE RELEASE Covington, KY, November 19, 2018 - Bexion Pharmaceuticals, Inc., a clinical - stage biopharmaceutical company focused on rare brain and solid tumors, announced today that a clinical oral report followed by poster [...]
National Cancer Institute (NCI) S elects Bexion as a Presenting Company FOR IMMEDIATE RELEASE Covington, KY ~ October 1 8 , 201 8 - Bexion Pharmaceuticals, Inc., a clini cal stage biotechnology company focused on developing [...]
Cincinnati Enquirer (Aug. 8, 2018) If you saw Bob Rulli on the street, you’d never guess he had cancer. He's the first person to receive a first-of-its-kind drug made in Cincinnati. (Photo: Kareem Elgazzar/The Enquirer) [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857